Kelun-Biotech Presents Promising Clinical Data at Upcoming ASCO Meeting
Event summary
- Kelun-Biotech will present data from three clinical studies at the 2026 ASCO Annual Meeting, including its TROP2 ADC sacituzumab tirumotecan (sac-TMT), RET inhibitor lunbotinib (A400/EP0031), and novel ADC SKB500.
- The ASCO presentations include an oral presentation of a Phase III trial evaluating sac-TMT plus pembrolizumab versus pembrolizumab for NSCLC.
- Lunbotinib’s efficacy and safety data from a pivotal Phase II study in RET fusion-positive NSCLC will also be presented orally.
- SKB500 will be featured in a rapid oral presentation as part of an open-label, first-in-human study.
The big picture
Kelun-Biotech's ASCO presentations highlight its growing prominence in the oncology space, particularly with its focus on ADCs. The company’s strategic partnerships with MSD and Ellipses Pharma demonstrate a deliberate effort to expand its global reach. The data presented will be critical for shaping investor sentiment and influencing future development decisions for these key assets.
What we're watching
- Clinical Validation
- The upcoming ASCO presentations will be crucial in validating the clinical efficacy and safety of sac-TMT, particularly given its global commercialization partnership with MSD and existing approvals in China.
- Regulatory Pathway
- The FDA’s progress on lunbotinib, currently in Phase II trials, will be a key indicator of its potential for broader international market access beyond Greater China.
- Pipeline Depth
- The early-stage data on SKB500 will reveal the potential of Kelun-Biotech’s OptiDC platform and its ability to generate a robust pipeline of novel ADCs.
Related topics